Unknown

Dataset Information

0

Neuromodulation for treatment-resistant depression.


ABSTRACT: Treatment-resistant depression affects at least 1-3% of the US population. This article reviews the current state of focal neuromodulation therapies for treatment-resistant depression, focusing on those treatments published clinical data. These include transcranial magnetic stimulation, transcranial direct current stimulation, magnetic seizure therapy, vagus nerve stimulation, direct cortical stimulation, and deep brain stimulation among others. Of these, only two (transcranial magnetic stimulation and vagus nerve stimulation) currently have US Food and Drug Administration approval for the treatment of depression.

SUBMITTER: Holtzheimer PE 

PROVIDER: S-EPMC3506219 | biostudies-literature | 2012

REPOSITORIES: biostudies-literature

altmetric image

Publications

Neuromodulation for treatment-resistant depression.

Holtzheimer Paul E PE   Mayberg Helen S HS  

F1000 medicine reports 20121101


Treatment-resistant depression affects at least 1-3% of the US population. This article reviews the current state of focal neuromodulation therapies for treatment-resistant depression, focusing on those treatments published clinical data. These include transcranial magnetic stimulation, transcranial direct current stimulation, magnetic seizure therapy, vagus nerve stimulation, direct cortical stimulation, and deep brain stimulation among others. Of these, only two (transcranial magnetic stimulat  ...[more]

Similar Datasets

| S-EPMC4754006 | biostudies-literature
2013-03-29 | GSE45603 | GEO
2013-03-29 | E-GEOD-45603 | biostudies-arrayexpress
| S-EPMC6721276 | biostudies-literature
| S-EPMC3936783 | biostudies-literature
| S-EPMC8047832 | biostudies-literature
| S-EPMC4423538 | biostudies-literature
| S-EPMC5509631 | biostudies-literature
2013-04-01 | GSE45468 | GEO
| S-EPMC5729118 | biostudies-other